4.3  0.255 (6.3%)		06-12 14:18
Open: 4.05 High: 4.36 Volume: 370,111		Pre. Close: 4.045 Low: 4.03 Market Cap: 215(M)

Short term
Mid term
Targets	6-month :	5.6	1-year :	6.35
Resists	First :	4.79	Second :	5.44
Pivot price	4.32
Supports	First :	3.75	Second :	3.12
MAs	MA(5) :	4.03	MA(20) :	4.35
	MA(100) :	5.54	MA(250) :	6.36
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	31.1	D(3) :	19.2
RSI	RSI(14): 46
52-week	High :	9.82	Low :	3.75

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ HELP ] has closed below upper band by 48.6%. Bollinger Bands are 42.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	4.13 - 4.16	4.16 - 4.18
Low:	3.83 - 3.86	3.86 - 3.89
Close:	4 - 4.05	4.05 - 4.1

Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.

Wed, 22 Apr 2026
[SCHEDULE 13G/A] CYBIN INC. Amended Passive Investment Disclosure - Stock Titan

Sat, 10 Jan 2026
Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq - Yahoo Finance

Tue, 06 Jan 2026
Cybin Inc. (HELP) - Zacks Investment Research

Wed, 31 Dec 2025
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - Seeking Alpha

Tue, 30 Dec 2025
Cybin Initiates At-The-Market Equity Program of up to US$100 Million - Business Wire

Tue, 30 Dec 2025
Cybin launches $100 million at-the-market equity program - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	50 (M)
Shares Float	102 (M)
Held by Insiders	5.7 (%)
Held by Institutions	48.6 (%)
Shares Short	2,540 (K)
Shares Short P.Month	3,340 (K)

EPS	-4.31
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.05
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-32 %
Return on Equity (ttm)	-55.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.4
Qtrly Earnings Growth	0 %
Operating Cash Flow	-112 (M)
Levered Free Cash Flow	-70 (M)

PE Ratio	-1.01
PEG Ratio	0
Price to Book value	86.8
Price to Sales	0
Price to Cash Flow	-1.93

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.